Aragen Launches CHOMax™, an Accelerated Platform for DNA to IND-Enabling Clinical Supply in ~10 MonthsAccelerated pathway: ...

The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...

Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.

Aragen's new cell line development and early manufacturing platform, CHOMax, can cut timelines to approximately 10 months.

In the race to bring new biologics to market, development teams are constantly balancing speed, quality, and regulatory ...

BOSTON & SAN CARLOS, Calif.--(BUSINESS WIRE)--Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System ...